Incretin-based therapies, glucometabolic health and endovascular inflammation

Current Pharmaceutical Design

Volumn 20, Issue 31, 2014, Pages 4953-4960

  Rizzo, Manfredi ^a,b,c   Nikolic, Dragana ^a   Banach, Maciej ^d   Patti, Angelo Maria ^a   Montalto, Giuseppe ^a   Rizvi, Ali A ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Euro Mediterranean Institute of Science and Technology   (Italy)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Incretin; Lipoproteins; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; BIOLOGICAL MARKER; EXENDIN 4; GASTROINTESTINAL HORMONE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; LIPID; LIPOPROTEIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE;

ADVERSE DRUG REACTION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG THERAPY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEART MUSCLE CELL; HUMAN; INCRETIN BASED THERAPY; INSULIN RELEASE; LIPOPROTEIN METABOLISM; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION; DECREASED APPETITE; DIABETIC PATIENT; DIET RESTRICTION; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEADACHE; HORMONAL REGULATION; HORMONE RESPONSE; INFECTION; OBESITY; PANCREATITIS; SATIETY; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; INFLAMMATION; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; HUMANS; INCRETINS; INFLAMMATION; LIPOPROTEINS; METABOLIC SYNDROME X;

EID: 84906216623     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666131206102255     Document Type: Article

References (110)

1. Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev 2008; 4(2): 101-109.
2. Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol (Oxf) 2009; 70(3): 343-353.
3. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15(6): 540-559.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32(1): 193-203.
5. Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 2013; 9(1): 17-29.
6. Paolisso G, Monami M, Marfella R, Rizzo MR, Mannucci E. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Adv Ther 2012; 29(3): 218-233.
7. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother 2008; 9(10): 1705-1720.
8. Wideman RD, Kieffer TJ. Mining incretin hormone pathways for novel therapies. Trends Endocrinol Metab 2009; 20(6): 280-286.
9. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009; 31(11): 2472-2488.
10. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010; 30(5): 463-484.
11. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20(4): 224-235.
12. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011; 34(2): 369-374.
13. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36(6): 843-854.
14. NCT01179048. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation (LEADER®). Available from: http://clinicaltrials.gov/ct2/show/NCT01179048. [Accessed 2012].
15. NCT01107886. Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications (SAVOR- TIMI 53). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01107886?term=SAVOR+TIMI&rank=1 [Accessed 2012].
16. NCT00790205. Sitagliptin Cardiovascular Outcome Study (0431-082 AM1) (TECOS). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00790205?term=TECOS&rank=1 [Accessed 2012].
17. NCT00968708. Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00968708?term=alogliptin+acute+coronary+syndrome&rank=1 [Accessed 2012].
18. NCT01001962. Double Blind Placebo Study of Vildagliptin in Prehypertensives Type II Diabetics (Prediab) (PREDIAB). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01001962?term=nct01001962&rank=1 [Accessed 2012].
19. Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2008; 17(6): 845-853.
20. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26(3): 268-278.
21. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32(1): 84-90.
22. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373(9662): 473-481.
23. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32(7): 1224-1230.
24. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52(10): 2046-2055.
25. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374(9683): 39-47.
26. Ali S, Fonseca V. Saxagliptin overview: special focus on safety and adverse effects. Expert Opin Drug Saf 2013; 12(1): 103-109.
27. Frederich R, McNeill R, Berglind N, Fleming D, Chen R. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr 2012; 4(1): 36.
28. Knop FK, Holst JJ, Vilsboll T. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. IDrugs 2008; 11(7): 497-501.
29. Nauck M, Brandle M, Vaag A, et al. editors. The once-daily human GLP-1 analog liraglutide substantially reduces HbA1c in subjects with type 2 diabetes, irrespective of HbA1c at baseline. American Diabetes Association 68th Scientific Session; 2008 June 6-10; San Francisco, California.
30. Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol 2008; 158(6): 773-784.
31. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27(6): 1335-1342.
32. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27(8): 1915-1921.
33. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29(12): 2632-2637.
34. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28(10): 1556-1568.
35. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76(1): 132-138.
36. Sunkara G, Sabo R, Wang Y, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol 2007; 47(9): 1152-1158.
37. Halimi S, Debaty I, Villaret L, Muller M. [New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?]. Rev Med Interne 2008; 29(11): 881-890.
38. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154(9): 602-613.
39. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012; 34(6): 1247-1258 e22.
40. Madsbad S. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. Eur J Intern Med 2012; 23(2): 132-136.
41. Blonde L, Montanya E. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Diabetes Obes Metab 2012; 14(Suppl 2): 20-32.
42. Scheen AJ. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med 2012; 23(2): 126-131.
43. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48(5): 592-598.
44. Tofovic DS, Bilan VP, Jackson EK. Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome. Clin Exp Pharmacol Physiol 2010; 37(7): 689-691.
45. Mannucci E, Dicembrini I. Incretin-based therapies and cardiovascular risk. Curr Med Res Opin 2012; 28(5): 715-721.
46. Deacon CF, Marx N. Potential cardiovascular effects of incretin-based therapies. Expert Rev Cardiovasc Ther 2012; 10(3): 337-351.
47. Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010; 53(10): 2256-2263.
48. Liu H, Hu Y, Simpson RW, Dear AE. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. J Endocrinol 2008; 196(1): 57-65.
49. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287(6): E1209-E1215.
50. Forst T, Michelson G, Ratter F, et al. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 2012; 29(9): 1115-1118.
51. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376(9739): 431-439.
52. Courreges JP, Vilsboll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008; 25(9): 1129-1131.
53. Kinalska I, Bednarska-Chabowska D, Adamiec-Mroczek J, Hak L. The influence of incretin mimetics on cardiovascular risk factors in diabetes. ISRN Endocrinol 2012; 2012: 625809.
54. Plutzky J, Garber AJ, et al. The once daily human GLP-1-analogue, liraglutide significantly reduces markers of cardiovascular risk in type 2 diabetes: a metaanalysis of six clinical trials. Eur Heart J 2009; pp.917-919.
55. Monami M. Glucagon-like peptide-1 and diabetes. Exp Diabetes Res 2011; 2011: 901954.
56. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370(9593): 1129-1136.
57. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59(4): 1030-1037.
58. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009; 201(1): 59-66.
59. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33(7): 1607-1609.
60. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010; 3(2): 195-201.
61. Theiss HD, Brenner C, Engelmann MG, et al. Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis. Int J Cardiol 2010; 145(2): 282-284.
62. Lim S, Choi SH, Shin H, et al. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One 2012; 7(4): e35007.
63. Rizzo M, Patti A, Di Bartolo V, et al., editors. Effect of liraglutide on carotid intima-media thickness in patients with type-2 diabetes: a 4-month prospective study. 72nd Scientific Sessions of the American Diabetes Association; 2012 June 8-12; Philadelphia, PA, USA: Diabetes 2012.
64. Farr S, Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol 2012; 23(1): 56-61.
65. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011; 13(4): 302-312.
66. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs 2009; 18(10): 1495-1503.
67. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012; 29(1): 14-25.
68. Monami M, Vitale V, Ambrosio ML, et al. Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials. Adv Ther 2012; 29(9): 736-746.
69. Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol 2011; 10: 61.
70. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 2010; 33(5): 1028-1030.
71. Kesavadev J, Shankar A, Krishnan G, Jothydev S. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. Int J Gen Med 2012; 5: 317-322.
72. Rizvi AA, Montalto G, Patti AM, Rizzo M. Oxidative stress and small, dense low-density lipoproteins: current and future perspectives. Expert Rev Endocrinol Metab 2012; 7(4): 415-417.
73. Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 2007; 115(8): 477-482.
74. Rizzo M, Berneis K. Who needs to care about small, dense low-density lipoproteins? Int J Clin Pract 2007; 61(11): 1949-1956.
75. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9(5): 531-532.
76. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9(5): 533-571.
77. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012; 35(10): 2076-2082.
78. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124(21): 2338-2349.
79. Eliasson B, Moller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 2012; 55(4): 915-925.
80. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58(2): 157-166.
81. Terasaki M, Nagashima M, Watanabe T, et al. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism 2012; 61(7): 974-977.
82. Nagashima M, Watanabe T, Terasaki M, et al. Native incretins prevent the development of atherosclerotic lesions in apolipo-protein E knockout mice. Diabetologia 2011; 54(10): 2649-2659.
83. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993; 328(17): 1220-1225.
84. Kolovou GD, Mikhailidis DP, Nordestgaard BG, Bilianou H, Panotopoulos G. Definition of postprandial lipaemia. Curr Vasc Pharmacol 2011; 9(3): 292-301.
85. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9(3): 258-270.
86. Mihas C, Kolovou GD, Mikhailidis DP, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 2011; 9(3): 271-280.
87. Wright EE, Jr., Stonehouse AH, Cuddihy RM. In support of an early polypharmacy approach to the treatment of type 2 diabetes. Diabetes Obes Metab 2010; 12(11): 929-940.
88. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27(Suppl 3): 57-64.
89. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011; 34(11): 2474-2476.
90. Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 2011; 27(4): 362-372.
91. Fadini GP, de Kreutzenberg SV, Gjini R, Avogaro A. The metabolic syndrome influences the response to incretin-based therapies. Acta Diabetol 2011; 48(3): 219-225.
92. Yamaoka-Tojo M, Tojo T, Takahira N, et al. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol 2010; 9: 17.
93. Viswanathan P, Chaudhuri A, Bhatia R, et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007; 13(5): 444-450.
94. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; 8(4): 419-428.
95. Colagiuri S, Frid A, Zdravkovic M, et al. e, editors. The once-daily human GLP-1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes. American Diabetes Association 68th Scientific Session; 2008 June 6-10; San Francisco, CA.
96. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24(1): 275-286.
97. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30(8): 1448-1460.
98. Bergenstal R, Kim T, Yan P, al e. Exenatide once weekly improved cardiometabolic risk factors in subjects with type 2 diabetes during one year of treatment. Diabetes 2009; 58(Suppl. 1): A43.
99. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9(6): 698-705.
100. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13(26): 3540-3553.
101. Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011; 60(4): 1246-1257.
102. Pacana T, Fuchs M. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. Clin Liver Dis 2012; 16(3): 599-613.
103. FDA. Victoza® liraglutide: FULL PRESCRIBING INFORMATION. Novo Nordisk; Available from: http://www.novo-pi.com/victoza.pdf [Accessed 2012].
104. Byetta.com. BYETTA® (exenatide) Injection: FULL PRESCRIBING INFORMATION. Amylin Pharmaceuticals; Available from: http://documents.byetta.com/Byetta_PI.pdf [Accessed 2012].
105. FDA. ONGLYZA (saxagliptin) tablets: FULL PRESCRIBING INFORMATION. Bristol-Myers Squibb; Available from: http://packageinserts.bms.com/pi/pi_onglyza.pdf [Accessed 2012].
106. FDA. JANUVIA® (sitagliptin) Tablets: FULL PRESCRIBING INFORMATION. Merck Sharp & Dohme; Available from: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_ pi.pdf [Accessed 2012].
107. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33(11): 2349-2354.
108. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141(1): 150-156.
109. Kunjathaya P, Ramaswami PK, Krishnamurthy AN, Bhat N. Acute necrotizing pancreatitis associated with vildagliptin. JOP 2013; 14(1): 81-84.
110. Lebovitz HE, Banerji MA. Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease. Diabetes Technol Ther 2012; 14(Suppl 1): S43-S50.